诊断学理论与实践

诊断学理论与实践 >

2020 , Vol. 19 >Issue 02: 139 - 144

DOI: https://doi.org/10.16150/j.1671-2870.2020.02.008

论著

血清尿酸水平与帕金森病发病间关系的前瞻性研究

展开
  • 1.上海黄浦区五里桥街道社区卫生服务中心a. 预防保健科,b. 行政科,上海 200023
    2.上海交通大学医学院附属瑞金医院神经内科,上海 200025

收稿日期: 2019-10-10

  网络出版日期: 2020-04-25

基金资助

国家重点研发计划项目(2016YFC1306000)

收起

Serum uric acid and Parkinson disease: a population-based prospective study

Expand
  • 1a. Department of Prevention and Healthcare, 1b. Department of Administration,Wuliqiao Community Health Service Center, Huangpu District, Shanghai 200023, China
    2. Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2019-10-10

  Online published: 2020-04-25

Fold

摘要

目的：前瞻性评估血清尿酸（uric acid, UA）水平检测对帕金森病（Parkinson disease, PD）发病的预测作用。方法：以上海某社区正常老年人群的随访队列（≥50岁）为基础,随访人群2011年的基线血清UA水平,统计2011年至2017年底新发PD的病例数,利用Cox回归分析血清UA水平与PD发病间的关系。结果：Cox单因素回归分析结果未发现高UA血症与PD发病间存在统计学相关性[风险比（hazard ratio,HR）=2.072,95%置信区间（confidence interval, CI）为0.701~6.121,P=0.188]。在校正年龄、性别等混杂因素后,依旧未发现血清UA水平对PD发病存在影响（HR=3.368,95%CI为0.904~12.546, P=0.070）。结论：本次针对正常老年人群的前瞻性队列研究中,未发现高UA血症与PD发病间存在统计学相关性,关于高血清UA水平对PD的保护作用还有待进一步行更大样本的前瞻性队列研究来验证。

关键词： 血清尿酸; 帕金森病; 队列研究

本文引用格式

邵丹丹, 付洋, 罗琪, 陈捷, 马建芳, 黄雷 . 血清尿酸水平与帕金森病发病间关系的前瞻性研究[J]. 诊断学理论与实践, 2020 , 19(02) : 139 -144 . DOI: 10.16150/j.1671-2870.2020.02.008

Abstract

Objective: To explore the association of serum uric acid (UA) level and the risk of Parkinson disease (PD) in Chinese. Methods: The population-based cohort study was conducted in subjects over 50 years old in districts of Shanghai from 2011 through end of 2017. The individuals had base line serum uric acid levels determined and were followed for incidence of PD. The association of serum uric acid level and risk of PD was analyzed with Cox regression. Results: The Cox regression analysis revealed no significant association between hyperuricemia and the incidence of PD without (HR=2.072, 95%CI: 0.701-6.121, P=0.188), or with adjustment with age, gender and other confoun-ding factors (HR=3.368, 95%CI: 0.904-12.546, P=0.070). Conclusion: The prospective study shows no significant asso-ciation between hyperuricemia and the incidence of PD.

Key words： Serum uric acid; Parkinson disease; Cohort study

参考文献

[1] Zhang ZX, Roman GC, Hong Z, et al. Parkinson's di-sease in China: prevalence in Beijing, Xian, and Shanghai[J]. Lancet, 2005, 365(9459):595-597.
[2] Kalia LV, Lang AE. Parkinson's disease[J]. Lancet, 2015, 386(9996):896-912.
[3] Jiang T, Sun Q, Chen S. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease[J]. Prog Neurobiol, 2016, 147:1-19.
[4] Fabbrini E, Serafini M, Colic Baric I, et al. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects[J]. Diabetes, 2014, 63(3):976-981.
[5] Schlesinger I, Schlesinger N. Uric acid in Parkinson's disease[J]. Mov Disord, 2008, 23(12):1653-1657.
[6] Chen H, Mosley TH, Alonso A, et al. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study[J]. Am J Epidemiol, 2009, 169(9):1064-1069.
[7] Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease[J]. Am J Epidemiol, 2007, 166(5):561-567.
[8] de Lau LM, Koudstaal PJ, Hofman A, et al. Serum uric acid levels and the risk of Parkinson disease[J]. Ann Neurol, 2005, 58(5):797-800.
[9] Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008[J]. Arthritis Rheum, 2011, 63(10): 3136-3141.
[10] Hong JY, Lan TY, Tang GJ, et al. Gout and the risk of dementia: a nationwide population-based cohort study[J]. Arthritis Res Ther, 2015, 17:139.
[11] Ma JF, Qiao Y, Gao X, et al. A community-based study of risk factors for probable rapid eye movement sleep behavior disorder[J]. Sleep Med, 2017, 30:71-76.
[12] Jain S, Ton TG, Boudreau RM, et al. The risk of Parkinson disease associated with urate in a community-based cohort of older adults[J]. Neuroepidemiology, 2011, 36(4):223-229.
[13] 崔诗爽, 陈生弟, 王刚. 帕金森病体液生物标志物研究进展[J]. 诊断学理论与实践, 2018, 17(4):471-476.
[14] Gao X, O'Reilly ÉJ, Schwarzschild MA, et al. Prospective study of plasma urate and risk of Parkinson disease in men and women[J]. Neurology, 2016, 86(6):520-526.
[15] 许亚运, 杨任民, 方明娟, 等. 磷脂酶A2G6基因突变的青年型帕金森病1例[J]. 安徵医学, 2019, 40(5):594-595.
[16] O'Reilly EJ, Gao X, Weisskopf MG, et al. Plasma urate and Parkinson's disease in women[J]. Am J Epidemiol, 2010, 172(6):666-670.
[17] de Lau LM, Koudstaal PJ, Hofman A. Parkinson disease is more prevalent than people think. Research results[J]. Lancet Neurol, 2006, 5(6):525-535.
[18] Wang YL, Wang YT, Li JF, et al. Body mass index and risk of parkinson's disease: a dose-response meta-analysis of prospective studies[J]. PLoS One, 2015, 10(6):e0131778.
[19] de Lau LM, Koudstaal PJ, Hofman A, et al. Serum cholesterol levels and the risk of Parkinson's disease[J]. Am J Epidemiol, 2006, 164(10):998-1002.
[20] Hu G, Antikainen R, Jousilahti P, et al. Total cholesterol and the risk of Parkinson disease[J]. Neurology, 2008, 70(21):1972-1979.
[21] Vikdahl M, Bäckman L, Johansson I, et al. Cardiovascular risk factors and the risk of Parkinson's disease[J]. Eur J Clin Nutr, 2015, 69(6):729-733.
[22] Qiu C, Hu G, Kivipelto M, et al. Association of blood pressure and hypertension with the risk of Parkinson di-sease: the National FINRISK Study[J]. Hypertension, 2011, 57(6):1094-1100.
[23] De Pablo-Fernandez E, Goldacre R, Pakpoor J, et al. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study[J]. Neurology, 2018, 91(2):e139-e142.
[24] Lu L, Fu DL, Li HQ, et al. Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies[J]. PLoS One, 2014, 9(1):e85781.
[25] Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease[J]. Diabetes Care, 2011, 34(4):910-915.
[26] Biosa A, Outeiro TF, Bubacco L, et al. Diabetes mellitus as a risk factor for Parkinson's disease: A molecular point of view[J]. Mol Neurobiol, 2018, 55(11):8754-8763.
[27] Palacios N, Gao X, Mc Cullough ML, et al. Obesity, diabetes, and risk of Parkinson's disease[J]. Mov Disord, 2011, 26(12):2253-2259.
[28] Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention[J]. Lancet Neurol, 2016, 15(12):1257-1272.
[29] Tan LC, Koh WP, Yuan JM, et al. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study[J]. Am J Epidemiol, 2008, 167(5):553-560.
[30] Chen H, Zhang SM, Hernán MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease[J]. Arch Neurol, 2003, 60(8):1059-1064.
[31] Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology[J]. Cell Tissue Res, 2004, 318(1):121-134.
[32] 刘剑, 沈平雁, 俞正娟, 等. 上海浦东地区高尿酸血症的流行现状及影响因素分析[J]. 中国中西医结合肾病杂志, 2017, 18(5):401-404.
[33] Liu R, Han C, Wu D, et al. Prevalence of hyperuricemia and gout in mainland china from 2000 to 2014: A systematic review and meta-analysis[J]. Biomed Res Int, 2015, 2015:762820.
Options
文章导航

/

〈 〉